Document:

Collateral Assignment

 Exhibit 10.8 
 COLLATERAL ASSIGNMENT 
 COLLATERAL ASSIGNMENT
made as of this 18th day of June, 2008 by Accentia Biopharmaceuticals, Inc., a Florida corporation (“Assignor”), to Laurus Master
Fund, Ltd., a Cayman Islands company (“Laurus”), Valens Offshore SPV I, Ltd. (as partial assignee of Laurus, “Valens Offshore I”), Valens Offshore SPV II, Corp. (“Valens Offshore II”), Valens U.S.
SPV I, LLC (as partial assignee of Laurus, “Valens US”), PSource Structured Debt Limited (as partial assignee of Laurus, “PSource”; and together with Laurus, Valens Offshore I, Valens Offshore II and Valens US,
individually, each an “Assignee” and collectively, the “Assignees”). 
 FOR VALUE RECEIVED, and as
collateral security for all debts, liabilities and obligations of Assignor to Assignees, now existing or hereafter arising under that certain Guaranty dated March 31, 2006 (as amended, modified, restated or supplemented from time to time, the
“Guaranty”), Assignor hereby assigns, transfers and sets over unto each Assignee all of its rights but not its obligations under that certain Royalty Agreement dated as of October 31, 2006 (as amended, modified, restated or
supplemented from time to time, the “Agreement”) between Assignor and Biovest International, Inc., a Delaware corporation (“Biovest”), including, without limitation, all moneys and claims for moneys due and/or to
become due to Assignor under the Agreement with respect to Royalties (as defined in the Agreement) or otherwise. 
 Assignor hereby
specifically authorizes and directs Biovest upon notice to it of this Assignment to make all payments due under or arising under the Agreement directly to Assignees and hereby irrevocably authorizes and empowers each Assignee to ask, demand,
receive, receipt and give acquittance for any and all amounts which may be or become due or payable, or remain unpaid at any time and times to Assignor by Biovest under and pursuant to the Agreement, and to endorse any checks, drafts or other orders
for the payment of money payable to Assignor in payment thereof, and in each Assignee’s discretion to file any claims or take any action or institute any proceeding, either in its own name or in the name of Assignor or otherwise, which such
Assignee may deem necessary or advisable in the premises. It is expressly understood and agreed, however, that no Assignee shall be required or obligated in any manner to make any demand or to make any inquiry as to the nature or sufficiency of any
payment received by it, or to present or file any claim or take any other action to collect or enforce the payment of any amounts which may have been assigned to such Assignee or to which such Assignee may be entitled hereunder at any time or times.

 Biovest, upon notice to it of this Assignment, is hereby authorized to recognize each Assignee’s claims to rights hereunder without
investigating any reason for any action taken by such Assignee or the validity or the amount of the obligations or existence of any default, or the application to be made by such Assignee of any of the amounts to be paid to said Assignee. Checks for
all or any part of the sums payable under this Assignment shall be drawn to the sole and exclusive order of an Assignee as directed by Assignees. 
 Without first obtaining the written consent of each Assignee, neither Assignor or Biovest shall (i) amend or modify the Agreement or (ii) agree to or suffer any amendment, extension, renewal, release, acceptance, forbearance,
modification or waiver with respect to any rights arising under the Agreement. 

 In the event Assignor declines to exercise any rights under the Agreement, each Assignee shall have the
right to enforce any and all such rights of Assignor against Biovest, whether or not such Assignee has commenced the exercise of its right and remedies under the Guaranty. 
 This Assignment shall be construed and enforced in accordance with and governed by the laws of the State of New York. 
 This Assignment may be executed in one or more counterparts each of which taken together shall constitute one and the same agreement. Any signature
delivered by a party by facsimile transmission or other electronic transmission shall be deemed an original signature hereto. 
 [Signature
Page Follows] 
  

 2 

 IN WITNESS WHEREOF, Assignor has duly executed this Assignment the day and year first above written.

  

			
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	By:	 	 /s/ James A. McNulty, CPA

	Name:	 	James A. McNulty, CPA
	Its:	 	Secretary/Treas

  
  

			
	 Biovest hereby consents and agrees
 to the
provisions as of the date first written above.

	
	BIOVEST INTERNATIONAL, INC.
		
	By:	 	 /s/ Alan M. Pearce

	Name:	 	Alan M. Pearce
	Its:	 	CFOSchedules to the Security Purchase Agreement

 EXHIBIT 10.9 
 Schedule A 
 LOCATION OF DEBTORS ACCOUNTS AND RECORDS 
 Accentia Biopharmaceuticals, Inc. 
 324 South Hyde Park Avenue, Suite 350

 Tampa, Florida 33606 
 Accentia Specialty Pharmacy, Inc.

 324 South Hyde Park Avenue, Suite 350 
 Tampa, Florida 33606

 AccentRx, Inc. 
 324 South Hyde Park Avenue, Suite 350

 Tampa, Florida 33606 

 Schedule B 
 PERMITTED LIENS 
 None. 

 Schedule C 
 FILINGS OR RECORDATIONS IN GOVERNMENTAL OR REGULATORY AUTHORITY, 
 AGENCY, OR RECORDING OFFICE 
 At closing, all security interests in the Collateral, except those granted hereby to the Secured Parties under this Agreement, will be released.

 Schedule D 
 DEBTORS’ STATE OF ORGANIZATION 
  

					
	 Company Name
	 	 Date of Incorporation
	 	 State of Incorporation

			
	Accentia Biopharmaceuticals, Inc.	 	March 26, 2002	 	Florida
		 		 	P02000033509
			
	Accentia Specialty Pharmacy, Inc.	 	April 27, 2004	 	Florida
		 		 	P04000068477
			
	AccentRX, Inc.	 	March 26, 2002	 	Florida
		 		 	P02000033522

 Schedule E 
 DEBTORS’ NAMES 
  

	(i)	Debtor Name: Accentia Biopharmaceuticals, Inc. 

  

	(ii)	Does not have any trade names 

  

	(iii)	Accentia, Inc. changed on May 11, 2005 

  

	(iv)	Accentia Specialty Pharmacy – merged on April 27, 2004 

  

	 	TEAMM Pharmaceuticals, Inc. – merged on April 30, 2003 

  

	 	Biovest International, Inc. – investment, majority shareholder on June 16, 2003 

  

	(i)	Debtor Name: Accentia Specialty Pharmacy, Inc. 

  

	(ii)	Does not have any trade names 

  

	(iii)	Has not used any name other than that stated for the preceding five years 

  

	(iv)	Was acquired and merged into Accentia Biopharmaceuticals, Inc. on April 27, 2004 

  

	(i)	Debtor Name: AccentRx, Inc. 

  

	(ii)	Does not have any trade names 

  

	(iii)	Has not used any name other than that stated for the preceding five years 

  

	(iv)	Was not acquired or merged into any Debtor within the past five years 

 Schedule F 
 Intellectual Property Related to SinuNase and Revimmune; including License Rights (In-Licensed) 
  

																									
	 Atty
 Docket #
	 	 Country
	 	 Status
	 	 Application #
	 	 Pub. #
	 	 Filing
 Date
	 	 Priority
	 	 Title
	 	 Owner/Assignee
	 	 Inventors
	 	 Patent
#
	 	 Issue
Date
	 	 Assoc.
Tech.

													
	ACZ-014	 	US	 	PENDING	 	11/777,890	 		 	7/13/2007	 	 2/9/07 - 60/900,593
 7/13/2006 - 60/830,528
	 	METHODS AND COMPOSITIONS FOR TREATING MUCOSAL INFLAMMATION	 	Accentia Biopharmaceuticals, Inc.	 	Francis E. O’Donnell, Jr.	 		 		 	SinuNase
													
	ACZ-014PC	 	PCT	 	PENDING	 	PCT/US2007/016000	 	WO 2008/008494 (1/17/08)	 	7/13/2007	 	 2/9/07 - 60/900,593
 7/13/2006 - 60/830,528
	 	METHODS AND COMPOSITIONS FOR TREATING MUCOSAL INFLAMMATION	 	Accentia Biopharmaceuticals, Inc.	 	Francis E. O’Donnell, Jr.	 		 		 	SinuNase
													
	ACZ-016PC	 	PCT	 	PENDING	 	PCT/US2007/080333	 	WO 2008/063756 (5/29/2008)	 	10/3/2007	 	 1/19/07 - 60/881,270
 10/3/06 -
60/849,028
	 	MUCOSALLY NON-IRRITATIVE AMPHOTERICIN B FORMULATIONS AND METHODS FOR TREATING NON-INVASIVE FUNGUS-INDUCED MUCOSITIS	 	Accentia, Biopharmaceuticals Inc.	 	Francis E. O’Donnell, Jr.; Donald Deroo	 		 		 	SinuNase
													
	ACZ-024-1	 	US	 	PENDING	 	61/027,736	 		 	2/11/2008	 		 	MUCOSALLY NON-IRRITATIVE AMPHOTERICIN B LIQUID FORMULATIONS AND METHODS FOR TREATING NON-INVASIVE FUNGUS-INDUCED MUCOSITIS	 	Accentia Biopharmaceuticals, Inc.	 	Francis E. O’Donnell, Jr.; Donald Deroo	 		 		 	SinuNase
													
	ACZ-026-1	 	US	 	PENDING	 	61/038,679	 		 	3/21/2008	 		 	DEVICES AND METHODS FOR DETERMINING THE EFFICACY OF A NON-SURGICAL INTERVENTION FOR THE TREATMENT OR PREVENTION OF CHRONIC RHINOSINUSITIS	 	Accentia Biopharmaceuticals, Inc.	 	Francis E. O’Donnell, Jr.; Angelos M. Stergiou; Susan Bonitz; Carlos Santos	 		 		 	SinuNase
													
	ACZ-027-1	 	US	 	PENDING	 	61/041,866	 		 	4/2/2008	 		 	FORMULATIONS, DEVICES AND METHODS FOR TREATING NON-INVASIVE FUNGUS-INDUCED MUCOSITIS	 	Accentia Biopharmaceuticals, Inc.	 	Francis E. O’Donnell, Jr.; Angelos M. Stergiou	 		 		 	SinuNase

																									
	 Atty
 Docket #
	 	 Country
	 	 Status
	 	 Application #
	 	 Pub. #
	 	 Filing
 Date
	 	 Priority
	 	 Title
	 	 Owner/Assignee
	 	 Inventors
	 	 Patent
#
	 	 Issue
Date
	 	 Assoc.
Tech.

													
	JHV-060.25	 	PCT	 	PENDING	 	PCT/US2007/78521	 	WO 2008/034074 (3/20/08)	 	9/14/2007	 	9/15/06 - 60/844,830	 	USE OF HIGH DOSE CYCLOPHOSPHAMIDE IN COMBINATION WITH ANTI-IDIOTYPIC VACCINES IN ANTI-CANCER THERAPY	 	Johns Hopkins University and Accentia Biopharmaceuticals, Inc.	 	Robert A. Brodsky; Richard J. Jones; Francis E. O’Donnell, Jr.; Susan Bonitz; Carlos Santos	 		 		 	Revimmune
													
	JHV-059.25	 	PCT	 	PENDING	 	PCT/US2007/78518	 	WO 2008/034071 (3/20/08)	 	9/14/2007	 	9/15/06 - 60/844,829	 	METHOD OF IDENTIFYING PATIENTS SUITABLE FOR HIGH-DOSE CYCLOPHOSPHAMIDE TREATMENT	 	Johns Hopkins University and Accentia Biopharmaceuticals, Inc.	 	Robert A. Brodsky; Richard J. Jones; Francis E. O’Donnell, Jr.; Susan Bonitz; Carlos Santos	 		 		 	Revimmune
													
	JHV-062.25	 	PCT	 	PENDING	 	PCT/US2007/81614	 	Anticipated Pub. Date: 5/8/08	 	10/17/2007	 	11/3/06 - 60/856,698	 	USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS IN COMBINATION WITH MONOCLONAL ANTIBODIES FOR TREATING IMMUNE DISORDERS	 	Johns Hopkins University and Accentia Biopharmaceuticals, Inc.	 	Robert A. Brodsky; Richard J. Jones; Francis E. O’Donnell, Jr.; Susan Bonitz; Carlos Santos	 		 		 	Revimmune
													
	RIZ-006-1	 	US	 	PENDING	 	60/989,628	 		 	11/21/2007	 		 	METHODS OF PROVIDING A SYSTEM OF CARE FOR A HIGH-DOSE REGIMEN OF AN OXAZAPHOSPHORINE DRUG	 	Accentia Biopharmaceuticals, Inc.	 	Francis E. O’Donnell, Jr.; Susan Bonitz; Carlos Santos	 		 		 	Revimmune
													
	ACZ-025-1	 	US	 	PENDING	 	61/038,033	 		 	3/19/2008	 		 	METHOD OF IDENTIFYING PATIENTS SUITABLE FOR HIGH-DOSE OXAZAPHOSPHORINE TREATMENT	 	Accentia Biopharmaceuticals, Inc.	 	Francis E. O’Donnell, Jr.; Susan Bonitz; Carlos Santos	 		 		 	Revimmune

  

																									
	 Atty
 Docket #
	 	 Country
	 	 Status
	 	 Application #
	 	 Pub. #
	 	 Filing
Date
	 	 Priority
	 	 Title
	 	 Owner/Assignee
	 	 Inventors
	 	 Patent
#
	 	 Issue
Date
	 	 Assoc.
Tech.

													
	RIZ-007-1	 	US	 	PENDING	 	61/022,774	 		 	1/22/2008	 		 	USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS FOR TREATMENT AND PREVENTION OF TRANSPLANT REJECTION	 	Johns Hopkins University and Accentia Biopharmaceuticals, Inc.	 	Robert Brodsky; Richard J. Jones; Susan Bonitz; Francis E. O’Donnell, Jr.; Carlos Santos	 		 		 	Revimmune

 SinuNase Agreements 
 1 - License Agreement between Mayo Foundation and Accentia Biopharmaceuticals, Inc., effective February 10, 2004, amended Dec. 23, 2004, Aug. 22, 2006, April 16, 2007, August 30, 2007, and
pending 
 2 - Marketing Agreement between TEAMM Pharmaceuticals, Inc. and IMMCO Diagnostics, Inc., effective June 30, 2005 
 3 - Option Agreement between Mayo Foundation and Accentia Biopharmaceuticals, Inc., effective December 6, 2005, amended July 20, 2006, May 9, 2007,
and pending 
 4 - Non-exclusive Sublicense between Accentia Specialty Pharmacy, Inc. and JCB Laboratories, LLC, effective January 1, 2007 

5 - Non-exclusive Sublicense between Accentia Specialty Pharmacy, Inc. and AnazaoHealth Corporation, effective February 1, 2007 
 Revimmune Agreements 
 1 - Sublicense Agreement between
Revimmune, LLC and Accentia Biopharmaceuticals, Inc., effective February 27, 2007, amended April 18, 2008 and June 16, 2008 
 2 - License
Agreement between Johns Hopkins University and Revimmune, LLC, effective February 20, 2006 
 3 - License Agreement between Accentia Biopharmaceuticals,
Inc. and Biovest International, Inc., pending 

 Schedule F 
 Intellectual Property Related to SinuNase and Revimmune; including License Rights (In-Licensed) 
 (Continued) 
 SinuNase 
 Trademarks

  

																	
	 Atty Docket #
	  	 Country
	  	 Trademark
	  	 Status
	  	 Owner
	  	 Application #
	  	 Filing Date
	  	 Reg. #
	  	 Reg. Date

									
	ACZ-0705	  	US	  	SINUNASE	  	FILED	  	Accentia Biopharmaceuticals, Inc.	  	78/540118	  	12/30/2004	  		  	
									
	ACZ-0705AU	  	Australia	  	SINUNASE	  	FILED	  	Accentia Biopharmaceuticals, Inc.	  	1092277	  	12/21/2005	  		  	
									
	ACZ-0705CA	  	Canada	  	SINUNASE	  	FILED	  	Accentia Biopharmaceuticals, Inc.	  	1242790	  	1/6/2005	  		  	
									
	ACZ-0705CTM	  	Europe	  	SINUNASE	  	Registered	  	Accentia Biopharmaceuticals, Inc.	  	4236147	  	1/10/2005	  	4236147	  	
									
	ACZ-0705JP	  	Japan	  	SINUNASE	  	FILED	  	Accentia Biopharmaceuticals, Inc.	  	2005-120651	  	12/22/2005	  	4977873	  	
									
	ACZ-0708	  	US	  	SINUTEST	  	Published	  	Accentia Biopharmaceuticals, Inc.	  	78/664701	  	7/6/2005	  		  	
									
	ACZ-0708AU	  	Australia	  	SINUTEST	  	FILED	  	Accentia Biopharmaceuticals, Inc.	  	1092278	  	12/21/2005	  	1092278	  	
									
	ACZ-0708CA	  	Canada	  	SINUTEST	  	Pending	  	Accentia Biopharmaceuticals, Inc.	  	1284178	  	12/21/2005	  		  	
									
	ACZ-0708CTM	  	Europe	  	SINUTEST	  	Published	  	Accentia Biopharmaceuticals, Inc.	  	4805248	  	12/23/2005	  		  	

 SinuNase 
 Trademarks 
  

																	
	 Atty Docket #
	  	 Country
	  	 Trademark
	  	 Status
	  	 Owner
	  	 Application #
	  	 Filing Date
	  	 Reg. #
	  	 Reg. Date

									
	ACZ-0708JP	  	Japan	  	SINUTEST	  	FILED	  	 Accentia Biopharmaceuticals,
 Inc.
	  	2005-120653	  	12/22/2005	  	5034132	  	
									
	ACZ-0709	  	US	  	SINULES	  	Published	  	 Accentia Biopharmaceuticals,
 Inc.
	  	78/678158	  	7/26/2005	  		  	
									
	ACZ-0710	  	US	  	FUNGINASE	  	Published	  	 Accentia Biopharmaceuticals,
 Inc.
	  	78/830090	  	3/6/2006	  		  	
									
	ACZ-0712	  	US	  	SINUSEPTIC	  	Published	  	 Accentia Biopharmaceuticals,
 Inc.
	  	78/936216	  	7/24/2006	  		  	
									
	ACZ-0714	  	US	  	MUCONASE	  	Published	  	 Accentia Biopharmaceuticals,
 Inc.
	  	77/36732	  	12/20/2007	  		  	

 Schedule pp 
 FEDERAL ASSIGNMENT OF CLAIMS ACT 
  

			
	Accentia Biopharmaceuticals, Inc.	  	NONE
		
	Accentia Specialty Pharmacy, Inc.	  	NONE
		
	AccentRx, Inc.	  	NONE

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00143-of-00352.parquet"}]]